NASDAQ:ZSAN

Zosano Pharma (ZSAN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.0002
$0.0002
50-Day Range
$0.52
$112.00
52-Week Range
$0.46
$37.45
Volume
5,685 shs
Average Volume
425,375 shs
Market Capitalization
$980.40
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ZSAN stock logo

About Zosano Pharma Stock (NASDAQ:ZSAN)

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

ZSAN Stock News Headlines

HOOK HOOKIPA Pharma Inc.
East Bay Business News
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Astellas Pharma
Zosano Pharma Corporation (ZSANQ)
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Zosano Pharma Corp (ZSANQ)
Zosano Pharma Reports Q1 Net Loss of $33.4M
Zosano Pharma Provides Corporate Update
See More Headlines
Receive ZSAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/13/2022
Today
5/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZSAN
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
$-29,920,000.00
Net Margins
-8,375.11%
Pretax Margin
-8,375.11%

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
$9.74 per share

Miscellaneous

Free Float
4,784,000
Market Cap
$980.40
Optionable
Not Optionable
Beta
3.30
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives


ZSAN Stock Analysis - Frequently Asked Questions

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.75) by $0.01. Zosano Pharma had a negative net margin of 8,375.11% and a negative trailing twelve-month return on equity of 177.06%.

When did Zosano Pharma's stock split?

Zosano Pharma's stock reverse split before market open on Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Zosano Pharma own?
When did Zosano Pharma IPO?

Zosano Pharma (ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

This page (NASDAQ:ZSAN) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners